First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid

被引：0
|
作者：
Lin, F. [1 ]
Huang, Y. [2 ]
Huang, Y. [2 ]
Lu, Y. [2 ]
Rao, X. [3 ]
Wang, X. [2 ]
Wang, F. [2 ]
Huang, X. [2 ]
机构：
[1] Tongji Univ, Shanghai East Hosp, Med Oncol, Shanghai, Peoples R China
[2] Hangzhou Adcoris Biopharma Co Ltd, Translat Med, Hangzhou, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 1, Med Oncol, Nanchang, Jiangxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335P
引用
收藏
页码：S354 / S355
页数：2
相关论文
共 50 条
  • [31] First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
    Kim, Sung-Bae
    Meric-Bernstam, Funda
    Kalyan, Aparna
    Babich, Aleksei
    Liu, Rong
    Tanigawa, Takahiko
    Sommer, Anette
    Osada, Motonobu
    Reetz, Frank
    Laurent, Dirk
    Wittemer-Rump, Sabine
    Berlin, Jordan
    TARGETED ONCOLOGY, 2019, 14 (05) : 591 - 601
  • [32] A first-in-human trial of the integrin beta-6-targeted antibody-drug conjugate, SGN-B6A, in patients with advanced solid tumors
    Calvo, E.
    Hollebecque, A.
    Dowlati, A.
    Piha-Paul, S. A.
    Galvao, V.
    Lopez, J.
    Sehgal, K.
    Bockorny, B.
    Braiteh, F.
    Peters, S.
    Sanborn, R. E.
    Zhou, P.
    Nazarenko, N.
    Patnaik, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S613 - S613
  • [33] Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
    Rottey, Sylvie
    Clarke, Jeffrey
    Aung, Kyaw
    Machiels, Jean-Pascal
    Markman, Ben
    Heinhuis, Kimberley M.
    Millward, Michael
    Lolkema, Martijn
    Patel, Sandip Pravin
    de Souza, Paul
    Duca, Matteo
    Curigliano, Giuseppe
    Santoro, Armando
    Koyama, Takafumi
    Brown, Michelle
    Vezina, Heather
    He, Chunsheng
    Chu, Quincy Siu-Chung
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 95 - 105
  • [34] DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
    Marathe, O.
    Cheng, Y.
    Spira, A. I.
    Hamilton, E. P.
    Rubinstein, M. M.
    Dong, X.
    Li, L.
    Lv, D.
    Shi, J.
    Gabrail, N.
    Amin, H.
    Wu, C.
    Zhu, Z.
    Qiu, Y.
    Gu, V.
    Qiu, X.
    Shi, R.
    Liu, L.
    Miao, P.
    Ueno, N. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S480 - S480
  • [35] First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.
    Ameratunga, Malaka
    Harvey, R. Donald
    Mau-Sorensen, Morten
    Thistlethwaite, Fiona
    Forssmann, Ulf
    Gupta, Manish
    Johannsdottir, Hrefna
    Ramirez-Andersen, Terrie
    Bohlbro, Mika Linette
    Losic, Nedjad
    Ervin-Haynes, Annette L.
    Lopez, Juanita Suzanne
    Vergote, Ignace
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
    Pegram, Mark D.
    Hamilton, Erika P.
    Tan, Antoinette R.
    Storniolo, Anna Maria
    Balic, Kemal
    Rosenbaum, Anton, I
    Liang, Meina
    He, Peng
    Marshall, Shannon
    Scheuber, Anita
    Das, Mayukh
    Patel, Manish R.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (08) : 1442 - 1453
  • [37] First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies
    Piha-Paul, Sarina A.
    Thein, Kyaw Z.
    De Souza, Paul
    Kefford, Richard
    Gangadhar, Tara
    Smith, Christopher
    Schuster, Shelly
    Zamboni, William C.
    Dees, Claire E.
    Markman, Ben
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1047 - 1056
  • [38] Trastuzumab-MCC-DM1 (TMAB-MCC-DM1), a first-in-class her2 antibody-drug conjugate (ADC) - A phase I study in patients (PTS) with Her2+metastatic breast cancer (BC)
    Beeram, M.
    Krop, I. E.
    Modi, S.
    Tolcher, A. W.
    Tibbitts, J.
    Rabbees, N.
    Girish, S.
    Lutzker, S. G.
    Holden, S. N.
    Burris, H. A.
    ANNALS OF ONCOLOGY, 2007, 18 : 21 - 21
  • [39] A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870).
    Boni, Valentina
    Rixe, Oliver
    Rasco, Drew
    Gomez-Roca, Carlos
    Calvo, Emiliano
    Morris, John C.
    Tolcher, Anthony W.
    Assadourian, Sylvie
    Guillemin, Helene
    Delord, Jean-Pierre
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [40] A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C
    Kim, Richard
    Leal, Alexis D.
    Parikh, Aparna
    Ryan, David P.
    Wang, Shining
    Bahamon, Brittany
    Gupta, Neeraj
    Moss, Aaron
    Pye, Joanna
    Miao, Harry
    Inguilizian, Haig
    Cleary, James M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (04) : 291 - 300
12345